Skip Navigation
Skip to contents

Diabetes Metab J : Diabetes & Metabolism Journal

Search
OPEN ACCESS

Search

Page Path
HOME > Search
3 "Fibric acids"
Filter
Filter
Article category
Keywords
Publication year
Authors
Funded articles
Original Article
Complications
Switching from Conventional Fibrates to Pemafibrate Has Beneficial Effects on the Renal Function of Diabetic Subjects with Chronic Kidney Disease
Rimi Izumihara, Hiroshi Nomoto, Kenichi Kito, Yuki Yamauchi, Kazuno Omori, Yui Shibayama, Shingo Yanagiya, Aika Miya, Hiraku Kameda, Kyu Yong Cho, So Nagai, Ichiro Sakuma, Akinobu Nakamura, Tatsuya Atsumi, on Behalf of the PARM-TD Study Group
Received October 15, 2023  Accepted November 22, 2023  Published online February 29, 2024  
DOI: https://doi.org/10.4093/dmj.2023.0370    [Epub ahead of print]
  • 828 View
  • 136 Download
AbstractAbstract PDFSupplementary MaterialPubReader   ePub   
Background
Fibrates have renal toxicity limiting their use in subjects with chronic kidney disease (CKD). However, pemafibrate has fewer toxic effects on renal function. In the present analysis, we evaluated the effects of pemafibrate on the renal function of diabetic subjects with or without CKD in a real-world clinical setting.
Methods
We performed a sub-analysis of data collected during a multi-center, prospective, observational study of the effects of pemafibrate on lipid metabolism in subjects with type 2 diabetes mellitus complicated by hypertriglyceridemia (the PARM-T2D study). The participants were allocated to add pemafibrate to their existing regimen (ADD-ON), switch from their existing fibrate to pemafibrate (SWITCH), or continue conventional therapy (CTRL). The changes in estimated glomerular filtration rate (eGFR) over 52 weeks were compared among these groups as well as among subgroups created according to CKD status.
Results
Data for 520 participants (ADD-ON, n=166; SWITCH, n=96; CTRL, n=258) were analyzed. Of them, 56.7% had CKD. The eGFR increased only in the SWITCH group, and this trend was also present in the CKD subgroup (P<0.001). On the other hand, eGFR was not affected by switching in participants with severe renal dysfunction (G3b or G4) and/or macroalbuminuria. Multivariate analysis showed that being older and a switch from fenofibrate were associated with elevation in eGFR (both P<0.05).
Conclusion
A switch to pemafibrate may be associated with an elevation in eGFR, but to a lesser extent in patients with poor renal function.
Reviews
Metabolic Risk/Epidemiology
Role of Fenofibrate Use in Dyslipidemia and Related Comorbidities in the Asian Population: A Narrative Review
Chaicharn Deerochanawong, Sin Gon Kim, Yu-Cheng Chang
Diabetes Metab J. 2024;48(2):184-195.   Published online January 26, 2024
DOI: https://doi.org/10.4093/dmj.2023.0168
  • 2,812 View
  • 394 Download
AbstractAbstract PDFSupplementary MaterialPubReader   ePub   
Hypertriglyceridemia and decreased high-density lipoprotein cholesterol (HDL-C) persist despite statin therapy, contributing to residual atherosclerotic cardiovascular disease (ASCVD) risk. Asian subjects are metabolically more susceptible to hypertriglyceridemia than other ethnicities. Fenofibrate regulates hypertriglyceridemia, raises HDL-C levels, and is a recommended treatment for dyslipidemia. However, data on fenofibrate use across different Asian regions are limited. This narrative review summarizes the efficacy and safety data of fenofibrate in Asian subjects with dyslipidemia and related comorbidities (diabetes, metabolic syndrome, diabetic retinopathy, and diabetic nephropathy). Long-term fenofibrate use resulted in fewer cardiovascular (CV) events and reduced the composite of heart failure hospitalizations or CV mortality in type 2 diabetes mellitus. Fenofibrate plays a significant role in improving irisin resistance and microalbuminuria, inhibiting inflammatory responses, and reducing retinopathy incidence. Fenofibrate plus statin combination significantly reduced composite CV events risk in patients with metabolic syndrome and demonstrated decreased triglyceride and increased HDL-C levels with an acceptable safety profile in those with high CV or ASCVD risk. Nevertheless, care is necessary with fenofibrate use due to possible hepatic and renal toxicities in vulnerable individuals. Long-term trials and real-world studies are needed to confirm the clinical benefits of fenofibrate in the heterogeneous Asian population with dyslipidemia.
Refocusing Peroxisome Proliferator Activated Receptor-α: A New Insight for Therapeutic Roles in Diabetes
Hannah Seok, Bong Soo Cha
Diabetes Metab J. 2013;37(5):326-332.   Published online October 17, 2013
DOI: https://doi.org/10.4093/dmj.2013.37.5.326
  • 2,807 View
  • 30 Download
  • 19 Crossref
AbstractAbstract PDFPubReader   

Although glucose-lowering treatment shows some risk lowering effects in cardiovascular diseases, risks of macrovascular and microvascular complications have still remained, and development of new therapeutic strategies is needed. Recent data have shown that peroxisome proliferator activated receptor-α (PPAR-α) plays a pivotal role in the regulation of lipid homeostasis, fatty acid oxidation, cellular differentiation, and immune response such as inflammation or vascularization related to diabetic complication. This review will re-examine the metabolic role of PPAR-α, summarize data from clinical studies on the effect of PPAR-α agonist in diabetes, and will discuss the possible therapeutic role of PPAR-α activation.

Citations

Citations to this article as recorded by  
  • Recent Insights into the Etiopathogenesis of Diabetic Retinopathy and Its Management
    Arpon Biswas, Abhijit Deb Choudhury, Sristi Agrawal, Amol Chhatrapati Bisen, Sachin Nashik Sanap, Sarvesh Kumar Verma, Mukesh Kumar, Anjali Mishra, Shivansh Kumar, Mridula Chauhan, Rabi Sankar Bhatta
    Journal of Ocular Pharmacology and Therapeutics.2024; 40(1): 13.     CrossRef
  • Counteracting health risks by Modulating Homeostatic Signaling
    Junqiang J. Tian, Mark Levy, Xuekai Zhang, Robert Sinnott, Rolando Maddela
    Pharmacological Research.2022; 182: 106281.     CrossRef
  • Moringa oleifera leaf extract influences oxidative metabolism in C2C12 myotubes through SIRT1-PPARα pathway
    Guglielmo Duranti, Mariateresa Maldini, Domenico Crognale, Stefania Sabatini, Federica Corana, Katy Horner, Roberta Ceci
    Phytomedicine Plus.2021; 1(1): 100014.     CrossRef
  • Diabetes risk associated with plasma epoxylipid levels
    John D. Imig
    eBioMedicine.2021; 66: 103331.     CrossRef
  • Genome-Wide Characterization of Alternative Splicing Events and Their Responses to Cold Stress in Tilapia
    Bi Jun Li, Zong Xian Zhu, Hui Qin, Zi Ning Meng, Hao Ran Lin, Jun Hong Xia
    Frontiers in Genetics.2020;[Epub]     CrossRef
  • PPARγ provides anti-inflammatory and protective effects in intrahepatic cholestasis of pregnancy through NF-κB pathway
    Yan Zhang, Xiaoping Huang, Jie Zhou, Yongxiang Yin, Ting Zhang, Daozhen Chen
    Biochemical and Biophysical Research Communications.2018; 504(4): 834.     CrossRef
  • Fermented Ginseng Contains an Agonist of Peroxisome Proliferator Activated Receptors α and γ
    Kentaro Igami, Yosuke Shimojo, Hisatomi Ito, Toshitsugu Miyazaki, Fusako Nakano, Yoshiki Kashiwada
    Journal of Medicinal Food.2016; 19(9): 817.     CrossRef
  • Long-term oral administration of osteocalcin induces insulin resistance in male mice fed a high-fat, high-sucrose diet
    Yu Yasutake, Akiko Mizokami, Tomoyo Kawakubo-Yasukochi, Sakura Chishaki, Ichiro Takahashi, Hiroshi Takeuchi, Masato Hirata
    American Journal of Physiology-Endocrinology and Metabolism.2016; 310(8): E662.     CrossRef
  • Peroxisome Proliferator-Activated Receptor-γGene Expression and Its Association with Oxidative Stress in Patients with Metabolic Syndrome
    Mehdi Hatami, Massoud Saidijam, Reza Yadegarzari, Shiva Borzuei, Alireza Soltanian, Marzieh Safi Arian, Mohammad Taghi Goodarzi
    Chonnam Medical Journal.2016; 52(3): 201.     CrossRef
  • Short Exposure to a High-Sucrose Diet and the First ‘Hit' of Nonalcoholic Fatty Liver Disease in Mice
    Flavia Fernandes-Lima, Thiago Luís Ribeiro Gomes Monte, Fernanda Amorim de Morais Nascimento, Bianca Martins Gregório
    Cells Tissues Organs.2016; 201(6): 464.     CrossRef
  • In vitro evaluation of dual agonists for PPARγ/β from the flower of Edgeworthia gardneri (wall.) Meisn
    Die Gao, Yong-lan Zhang, Pan Xu, Ye-xin Lin, Feng-qing Yang, Jian-hui Liu, Hai-wen Zhu, Zhi-ning Xia
    Journal of Ethnopharmacology.2015; 162: 14.     CrossRef
  • PPARα Agonist Fenofibrate Ameliorates Learning and Memory Deficits in Rats Following Global Cerebral Ischemia
    Ai-Guo Xuan, Yan Chen, Da-Hong Long, Meng Zhang, Wei-Dong Ji, Wen-Juan Zhang, Ji-Hong Liu, Le-Peng Hong, Xiao-Song He, Wen-Liang Chen
    Molecular Neurobiology.2015; 52(1): 601.     CrossRef
  • Modulation of Cardiac Connexin-43 by Omega-3 Fatty Acid Ethyl-Ester Supplementation Demonstrated in Spontaneously Diabetic Rats
    J. RADOSINSKA, L. H. KURAHARA, K. HIRAISHI, C. VICZENCZOVA, T. EGAN BENOVA, B. SZEIFFOVA BACOVA, V. DOSENKO, J. NAVAROVA, B. OBSITNIK, I. IMANAGA, T. SOUKUP, N. TRIBULOVA
    Physiological Research.2015; : 795.     CrossRef
  • Does Bosentan Protect Diabetic Brain Alterations in Rats? The Role of Endothelin‐1 in the Diabetic Brain
    Recep Demir, Elif Cadirci, Erol Akpinar, Yasemin Cayir, Hasan Tarik Atmaca, Harun Un, Celalettin Semih Kunak, Muhammed Yayla, Zafer Bayraktutan, Ilknur Demir
    Basic & Clinical Pharmacology & Toxicology.2015; 116(3): 236.     CrossRef
  • The effect of pioglitazone on aldosterone and cortisol production in HAC15 human adrenocortical carcinoma cells
    Zhi-qiang Pan, Ding Xie, Vivek Choudhary, Mutsa Seremwe, Ying-Ying Tsai, Lawrence Olala, Xunsheng Chen, Wendy B. Bollag
    Molecular and Cellular Endocrinology.2014; 394(1-2): 119.     CrossRef
  • Icariin Is A PPARα Activator Inducing Lipid Metabolic Gene Expression in Mice
    Yuan-Fu Lu, Yun-Yan Xu, Feng Jin, Qin Wu, Jing-Shan Shi, Jie Liu
    Molecules.2014; 19(11): 18179.     CrossRef
  • Canola Oil Influence on Azoxymethane-induced Colon Carcinogenesis, Hypertriglyceridemia and Hyperglycemia in Kunming Mice
    Xiao-Qiong He, Simon Angelo Cichello, Jia-Li Duan, Jin Zhou
    Asian Pacific Journal of Cancer Prevention.2014; 15(6): 2477.     CrossRef
  • Cardiovascular risks and benefits with oral drugs for Type 2 diabetes mellitus
    Emily Weidman-Evans, Steven M Metz, Jeffery D Evans
    Expert Review of Clinical Pharmacology.2014; 7(2): 225.     CrossRef
  • Enhanced pan‐peroxisome proliferator‐activated receptor gene and protein expression in adipose tissue of diet‐induced obese mice treated with telmisartan
    Aline Penna‐de‐Carvalho, Francielle Graus‐Nunes, Júlia Rabelo‐Andrade, Carlos Alberto Mandarim‐de‐Lacerda, Vanessa Souza‐Mello
    Experimental Physiology.2014; 99(12): 1663.     CrossRef

Diabetes Metab J : Diabetes & Metabolism Journal